Kaur R, Gulati M, Singh SK. Role of synbiotics in polysaccharide assisted colon targeted microspheres of mesalamine for the treatment of ulcerative colitis. Int J Biol Macromol. 2016;11:1–42.
Izzo R, Bevivino G, Monteleone G, Izzo R, Bevivino G, Monteleone G. Tofacitinib for the treatment of ulcerative colitis. Expert Opin Investig Drugs. 2016:1–21.
Centre N. Clinical guideline. Ulcerative colitis : Management in adults, children and young people. In: Clinical guideline: methods, evidence and recommendations. London: National institute for health and care excellence (NICE); 2013. p. 1–297.
César B, Lyra AC, Rocha R, Santana GO. Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis. World J Gastroenterol. 2014;20(28):9458–67.
Baumgart DC. In: Colitis UD c. B, editor. Crohn’s disease and ulcerative colitis; from epidemiology and immunobiology to a rational diagnostic and therapeutic approach. Berlin: Springer Netherlands; 2012. p. 1–741.
Peirce CB, Kalady MF. Ulcerative proctitis and anorectal Crohn’s disease. Fundam Anorectal Surg. 2019;29:531–54.
Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, et al. A comprehensive review and update on ulcerative colitis. Disease-a-Month. 2019;11:1–37.
Kameyama H, Nagahashi M, Shimada Y, Tajima Y, Ichikawa H. Genomic characterization of colitis- associated colorectal cancer. World J Surg Oncol. 2018;16:1–6.
Chandy G, Kurian G, Kurian S, Mathan M, Mathan VI, Patra S, et al. Risk of colorectal cancer in ulcerative colitis in India. J Gastroenterol Hepatol. 2005;20:705–9.
Lakatos PL, Lakatos L. Ulcerative proctitis: a review of pharmacotherapy. Expert Opin Pharmacother. 2008;9:741–50.
Article CAS PubMed Google Scholar
Morgado GC, Mancilla GP. Ulcerative proctitis. In: Ulcerative colitis – epidemiology, pathogenesis and complications. London: IntechOpen; 2011. p. 197–206.
Regueiro M, Loftus EV, Steinhart AH, Cohen RD. Clinical guidelines for the medical management of summary statement. Inflamm Bowel Dis. 2006;12:972–8.
Bokemeyer B, Hommes D, Gill I, Broberg P, Dignass A. Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing. J Crohn's Colitis. 2012;6:476–82.
Ghosh S, Shand A, Ferguson A. Clinical review - regular review ulcerative colitis. Br Med J. 2000;320:1119–23.
Bjerrum JT, Nielsen OH, Pittet V, Mueller C, Rogler G, Olsen J. Transcriptional analysis of left-sided colitis, pancolitis, and ulcerative colitis-associated dysplasia. Inflamm Bowel Dis. 2014;20:2340–52.
Bürger M, Schmidt C, Teich N, Stallmach A. Medical therapy of active ulcerative colitis. Visz Gastrointest Med Surg. 2015;31:236–45.
Nasseri-moghaddam S. Inflammatory bowel disease. Middle east J Dig Dis. 2012;4:77–89.
PubMed PubMed Central Google Scholar
Freeman HJ. Inflammatory bowel disease with cytoplasmic-staining antineutrophil cytoplasmic antibody and extensive colitis. Can J Gastroenterol Hepatol. 1998;12:279–83.
Koutroubakis IE. Recent advances in the management of distal ulcerative colitis. World J Gastrointest Pharmacol Ther. 2010;1:43–50.
Article PubMed PubMed Central Google Scholar
Conrad K, Roggenbuck D, Laass MW. Diagnosis and classification of ulcerative colitis. J Autoimmun. 2014;13:49–52.
Kuester D, Dalicho S, Mo K, Benedix F, Lippert H, Guenther T, et al. Synchronous multifocal colorectal carcinoma in a patient with delayed diagnosis of ulcerative pancolitis. Pathol Res Pract. 2008;204:905–10.
Teixeira FV, Hosne RS, Sobrado CW. Coloproctology systematic review of management of ulcerative colitis: a clinical update. J Coloproctol. 2015:1–8.
Pastorelli L, Pizarro TT, Cominelli F, Disease L, Unit GE, Milanese SD. Emerging drugs for the treatment of ulcerative colitis. Expert Opin Emerg Drugs. 2015;14:505–21.
Arora S, Malik TA. Inflammatory bowel disease: epidemiology. In: New insights into inflammatory bowel disease. London: IntechOpen; 2016. p. 1–20.
Nguyen GC, Chong CA, Chong RY. National estimates of the burden of inflammatory bowel disease among racial and ethnic groups in the United States. J Crohn's Colitis. 2014;8:288–95.
Finlay DG, Basu D, Sellin JH. Effect of race and ethnicity on perceptions of inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:503–7.
Kaplan GG. IBD: global variations in environmental risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2014;12:708–9.
Roberts-Thomson IC, Bryant RV, Costello SP. Uncovering the cause of ulcerative colitis. J Gastroenterol Hepatol. 2019;3:274–6.
Molodecky NA. Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol. 2010;6:339–46.
Abegunde AT, Muhammad BH, Bhatti O, Ali T. Environmental risk factors in inflammatory bowel diseases: evidence based environmental risk factors for inflammatory bowel diseases: evidence based literature review. World J Gastroenterol. 2016;22:6296–317.
Article CAS PubMed PubMed Central Google Scholar
Owczarek D, Rodacki T, Domagała-rodacka R, Cibor D, Mach T, Owczarek D, et al. Diet and nutritional factors in inflammatory bowel diseases. World J Gastroenterol. 2016;22:895–905.
Article CAS PubMed PubMed Central Google Scholar
Monif GR. Is ulcerative colitis a disease of a dysfunctional microbiota? Med Hypotheses. 2019;131:109300–2.
Massimo Campieri PG. Bacteria as a cause of ulcerative colitis. Gut J. 2001;48:132–5.
Hawrelak JA, Hons B, Myers SP. The causes of intestinal dysbiosis: a review. Altern Med Rev. 2004;9:180–97.
Loftus WV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504–17.
Kaplan GG, Pedersen BV, Andersson RE, Sands BE, Korzenik J. The risk of developing Crohn’s disease after an appendectomy: a population-based cohort study in Sweden and Denmark. Gut J. 2007;56:1387–92.
Gl R, Je E, Dm P, Pandeya N, Hospital RB. A role for the appendix in inflammatory bowel disease? Gastroenterology. 2002;125:1270–2.
Zuo T, Kamm MA, Colombel J-F, Ng SC. Urbanization and the gut microbiota in health and inflammatory bowel disease. Gastroenterol Hepatol. 2018;7:440–52.
Koutroubakis IE, Vlachonikolis IG, Kouroumalis EA. Role of appendicitis and appendectomy in the pathogenesis of ulcerative colitis: a critical review. Inflamm Bowel Dis. 2002;8:277–86.
Hart AL, Hendy P. The microbiome in inflammatory bowel disease and its modulation as a therapeutic manoeuvre. Proc Nutr Soc. 2014;73:452–6.
Article CAS PubMed Google Scholar
Knights D, Lassen KG, Xavier RJ. Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut. 2013;62:1505–10.
Article CAS PubMed Google Scholar
Takeshita K, Mizuno S, Mikami Y, Sujino T, Saigusa K, Matsuoka K, et al. A single species of Clostridium subcluster XIVa decreased in ulcerative colitis patients. Inflamm Bowel Dis. 2016;22:2802–10.
Hill DA, Artis D. Intestinal bacteria and the regulation of immune cell homeostasis. Annu Rev Immunol. 2009;28:623–67.
Bajer L, Kverka M, Kostovcik M, Macinga P, Dvorak J, Stehlikova Z, et al. Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis. World J Gastroenterol. 2017;23:45–8.
Machiels K, Joossens M, Sabino J, De Preter V, Arijs I, Eeckhaut V, et al. A decrease of the butyrate-p
Comments (0)